

Making malignancy measurable

A differentiated urine test for prostate cancer today.

A molecular platform built to connect cancer biology with precision medicine.

\$77M

Cumulative capital raised across the initiative¹

FDA Breakthrough Device Designation

Sentinel program, awarded 2020²

1,379 men

Prospective clinical program 432-man held-out evaluation³

THE PRODUCT AND THE CLINICAL NEED

miR Sentinel, powered by **Sentinel BioCompute**, helps providers assess high-grade prostate cancer risk and decide who needs prompt evaluation, while providing an ordinal score for monitoring. One urine specimen, collected without a rectal examination or blood draw, brings molecular assessment to **primary care, urology and integrated health systems**.

Different biology

A 48-target urinary exosomal small noncoding RNA panel measures a molecular layer distinct from serum protein and messenger RNA tests. Its potential regulatory biology opens a route to therapeutic discovery.

Graded clinical decisions

A calibrated probability of **Grade Group 3+ disease** maps to **Monitor, Further Evaluation or Expedited Evaluation**. The high-grade focus and graded priorities support decisions about the urgency of further evaluation.

E2E In-House Computation

We own computation from raw fluorescence to signed report. Our proprietary assay, clinical data and **CLIA-certified, CAP-accredited** laboratory form a reusable platform for new applications.

BLINDED VALIDATION | 432 MEN / 421 INFORMATIVE RESULTS

95.8%

of high-grade cancers assigned to further or expedited evaluation

96.2%

of Monitor results were free of high-grade cancer on biopsy

2.6x

high-grade disease enrichment in Expedited Evaluation

Commercial adoption has begun

First commercial order delivered to Walter Reed in September 2026.⁴ Revenue per laboratory test: **\$1,200 list price** and dedicated CPT 0424U. Scaling through provider adoption, institutional distribution and payer coverage.

From measurement to intervention

Our ambition is a measurement system for malignancy. Longitudinal studies, functional genomics and AI-enabled discovery could connect molecular profiles with **drug targets, treatment selection and response**, creating companion diagnostic and therapeutic partnerships across prostate cancer and other diseases.

THE NEXT CAPITAL BUILDS ADOPTION AND EXPANSION

Seeking growth capital and strategic partners for **health-system pilots** across primary care and urology, **payer evidence** and coverage, and **pharma co-development** in trial enrichment and companion diagnostics.

Sam Salman, Founder & CEO | **Nitin Yerram, MD**, CMO | **Qi Wei, PhD, DABCC**, Lab Director

sam.salman@mirnascientific.com | mirnascientific.com | North Brunswick, NJ | mirsentinel.com

1. Company-reported cumulative capital, including predecessor miR Scientific, LLC; Round 1 application. 2. FDA designation Q201687; not FDA clearance or approval. 3. Company validation, Aug. 2026; high-grade = Grade Group 3 or higher; 11/432 non-informative. 4. MMI confirmation, Sept. 28, 2026. Monitoring, therapeutic applications and other indications require further validation.